HIF-PH inhibitor
HIF prolyl hydroxylase inhibitor
- HIF is no longer degraded
- Stabilized HIF drives erythropoietin production → treats renal anemia
- Pharmacologic altitude — thrombosis and tumor-growth theoretical concerns follow the same biology
- Blocks hypoxia-inducible factor prolyl hydroxylase (HIF-PH) → HIF is no longer degraded
- Stabilized HIF drives erythropoietin production → treats renal anemia orally
- Pharmacologic altitude — thrombosis and tumor-growth theoretical concerns follow the same biology
Drugs with this mechanism (2)
- Roxadustat — Oral HIF-prolyl-hydroxylase inhibitor for CKD anemia in some countries; stimulates erythropoiesis, with thrombotic concerns.
- Vadadustat — Oral HIF prolyl-hydroxylase inhibitor for anemia of CKD in adults receiving dialysis.
All mechanisms · Open HIF-PH inhibitor in the interactive console ↗